

CITATION REPORT

List of articles citing

Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion

DOI: 10.1097/00007691-200108000-00001
Therapeutic Drug Monitoring, 2001, 23, 305-15.

Source: <https://exaly.com/paper-pdf/32714642/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
229	Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials. <i>Transplantation Proceedings</i> , 2001 , 33, 3241-4	1.1	50
228	The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. 2002 , 31, 45-9		65
227	Monitoring of mycophenolic acid in clinical transplantation. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 68-73.	3.2	36
226	International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 59-67	3.2	70
225	Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. 2002 , 11, 657-63		42
224	Monitoring mycophenolic acid. 2002 , 39, 173-83		49
223	High mycophenolic acid area under-the-curve values in renal transplant recipients on long-term mycophenolate mofetil treatment. <i>Transplantation Proceedings</i> , 2002 , 34, 2983-4	1.1	7
222	How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients. 2002 , 9, 211-4		21
221	Limited Sampling Strategy for the Estimation of Mycophenolic Acid Area under the Curve in Adult Renal Transplant Patients Treated with Concomitant Tacrolimus. 2002 , 48, 1497-1504		130
220	Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. 2003 , 3, 534-42		193
219	Liquid chromatography/mass spectrometry for therapeutic drug monitoring of immunosuppressants. 2003 , 492, 133-145		29
218	Impact of cyclosporine 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction. 2003 , 17, 144-50		25
217	Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. <i>British Journal of Clinical Pharmacology</i> , 2003 , 56, 188-97	3.8	51
216	The influence of cyclosporine on mycophenolic acid plasma concentrations: a review. 2003 , 17, 158-163		7
215	New Antiproliferative Immunosuppressive Agents. 2003 , 16, 401-413		
214	Treatment of chronic inflammatory demyelinating polyneuropathy. 2003 , 3, 233-46		2
213	Enteric-coated mycophenolate sodium. 2003 , 37, 1685-93		38

212	Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. 2003 , 43, 866-80		88
211	Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. <i>Therapeutic Drug Monitoring</i> , 2003 , 25, 609-22	3.2	122
210	Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. <i>Therapeutic Drug Monitoring</i> , 2003 , 25, 407-14	3.2	35
209	Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring?. <i>Therapeutic Drug Monitoring</i> , 2003 , 25, 137-57	3.2	98
208	Therapeutic monitoring of immunosuppressant drugs. Where are we?. 2004 , 42, 1204-11		27
207	Review of the immunosuppressant enteric-coated mycophenolate sodium. 2004 , 5, 1333-45		71
206	Monitoring of immunosuppressive therapy in renal transplanted patients. 2005 , 146, 73-86		3
205	Mycophenolates in transplantation. 2004 , 18, 485-92		79
204	Antiretroviral and immunosuppressive drug-drug interactions: an update. 2004 , 66, 532-41		55
203	Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. 2004 , 4, 1079-83		110
202	Lack of correlation between MMF dose and MPA level in pediatric and young adult cardiac transplant patients: does the MPA level matter?. 2004 , 4, 1495-500		30
201	Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. 2004 , 10, 492-502		100
200	Therapeutic monitoring of mycophenolic acid in liver transplant patients. 2004 , 10, 503-5		13
199	Simple reversed-phase ion-pair liquid chromatography assay for the simultaneous determination of mycophenolic acid and its glucuronide metabolite in human plasma and urine. 2004 , 805, 101-12		24
198	Monitoring immunosuppressive drugs. 2004 , 273-296		1
197	Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. <i>Clinical Pharmacokinetics</i> , 2004 , 43, 253-66	6.2	88
196	Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. 2004 , 10, 655-68		63
195	The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. <i>Transplantation Proceedings</i> , 2004 , 36, 2076-8	1.1	25

194	Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 347-51	3.2	40
193	Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 284-6	3.2	96
192	Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 620-5	3.2	37
191	Determinants of mycophenolic acid levels after renal transplantation. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 442-50	3.2	38
190	The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. <i>Transplantation</i> , 2005 , 80, S244-53	1.8	86
189	Clinical application of population pharmacokinetic methods developed for immunosuppressive drugs. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 727-32	3.2	15
188	Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. <i>Transplantation</i> , 2005 , 80, S235-43	1.8	38
187	Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo: evaluation of additive effects on rat blood lymphocyte function. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 123-31	3.2	18
186	Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: a computer simulation. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 163-7	3.2	27
185	Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 354-61	3.2	84
184	Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 315-21	3.2	30
183	Therapeutic drug monitoring of mycophenolic acid in cardiac transplant recipients: does it make sense?. 2005 , 10, 350-354		1
182	Simple High-Performance Liquid Chromatographic Assay, with Post-Column Derivatization, for Simultaneous Determination of Mycophenolic Acid and its Glucuronide Metabolite in Human Plasma and Urine. 2005 , 62, 363-371		8
181	Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. <i>European Journal of Clinical Pharmacology</i> , 2005 , 61, 507-16	2.8	57
180	Enteric-coated mycophenolate sodium for transplant immunosuppression. 2005 , 62, 2252-9		6
179	Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. 2005 , 106, 4381-8		67
178	Enteric-coated mycophenolate sodium - current and future use in transplant patients. 2005 , 1, 203-11		3
177	Mycophenolate mofetil for remission induction in severe lupus nephritis. 2005 , 100, c92-100		24

176	Immunosuppressant drug monitoring: is the laboratory meeting clinical expectations?. 2005 , 39, 119-27		24
175	A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. 2005 , 11, 495-505		108
174	Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus. 2005 , 24, 1614-8		34
173	Standard dose enteric-coated mycophenolate sodium (myfortic) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients. <i>Transplantation Proceedings</i> , 2005 , 37, 861-3 ^{1.1}		7
172	Impact of mycophenolate mofetil loading on drug exposure in the early posttransplant period. <i>Transplantation Proceedings</i> , 2005 , 37, 2320-3	1.1	8
171	Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. <i>Transplantation Proceedings</i> , 2005 , 37, 3749-51	1.1	25
170	Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 525-38	6.2	13
169	A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 837-47	6.2	53
168	Population pharmacokinetics of mycophenolic acid in renal transplant recipients. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 1083-96	6.2	81
167	Enteric-coated Mycophenolate Sodium (myfortic [®]): An Overview of Current and Future Use in Transplantation. 2006 , 66, 1??8		3
166	Individualization of mycophenolate mofetil dose in renal transplant recipients. 2006 , 7, 361-76		18
165	The weight of pharmacokinetic parameters for mycophenolic acid in prediction of rejection outcome: the receiver operating characteristic curve analysis. <i>Transplantation Proceedings</i> , 2006 , 38, 86-9	1.1	10
164	Pharmacokinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant. <i>Transplantation Proceedings</i> , 2006 , 38, 2482-5	1.1	6
163	Conversion from azathioprine to mycophenolate mofetil followed by calcineurin inhibitor minimization or elimination in patients with chronic allograft dysfunction. <i>Transplantation Proceedings</i> , 2006 , 38, 2872-8	1.1	4
162	Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. 2006 , 126, 1357-62		21
161	Within-patient variability of mycophenolic acid exposure: therapeutic drug monitoring from a clinical point of view. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 31-4	3.2	25
160	Fully automated analytical method for mycophenolic acid quantification in human plasma using on-line solid phase extraction and high performance liquid chromatography with diode array detection. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 505-11	3.2	13
159	A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT). <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 394-401	3.2	25

158	Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. <i>Transplantation</i> , 2006 , 82, 1413-8	1.8	43
157	Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. <i>Transplantation</i> , 2006 , 81, 541-6	1.8	52
156	Determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus: comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-tandem mass spectrometry. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 274-7	3.2	39
155	Therapeutic drug monitoring of mycophenolate mofetil in transplantation. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 145-54	3.2	275
154	Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. <i>Transplantation</i> , 2006 , 82, 1004-12	1.8	57
153	Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients. 2006 , 19, 44-53		2
152	Immunosuppression in pediatric solid organ transplantation: opportunities, risks, and management. 2006 , 10, 879-92		30
151	Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. 2006 , 31, 27-34		39
150	A comparison of the effect of ciclosporin and sirolimus on the pharmacokinetics of mycophenolate in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2006 , 62, 477-84	3.8	42
149	Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. <i>European Journal of Clinical Pharmacology</i> , 2007 , 63, 27-37	2.8	29
148	Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. 2006 , 6, 121-8		115
147	Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients. 2006 , 26, 1232-40		21
146	Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients. 2006 , 40, 1509-16		20
145	Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. 2006 , 17, 871-80		162
144	Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome. 2006 , 22, 2355-64		34
143	Therapeutic drug monitoring of mycophenolic acid. 2007 , 2, 1062-72		60
142	Is a standard fixed dose of mycophenolate mofetil ideal for all patients?. 2007 , 22, 3638-45		20
141	Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. 2007 , 2, 1147-55		47

140	Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?. 2007 , 3, 251-61		31
139	Therapeutic drug monitoring-based clozapine dosing recommendations. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 130-1	3.2	4
138	Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 299-304	3.2	36
137	Erratum. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 133	3.2	
136	Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 141-9	3.2	36
135	Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 353-60	3.2	36
134	Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 381-4	3.2	29
133	Effect of acidification on protein binding of mycophenolic acid. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 132-3	3.2	6
132	Internal standard selection for immunosuppressant drugs measured by high-performance liquid chromatography tandem mass spectrometry. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 131-2	3.2	18
131	Limited sampling strategy for the estimation of mycophenolic acid area under the plasma concentration-time curve in adult patients undergoing liver transplant. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 207-14	3.2	11
130	Report of the experience with enteric-coated sodium mycophenolate in a de novo population of kidney transplant recipients at high risk for delayed graft function. <i>Transplantation Proceedings</i> , 2007 , 39, 600-1	1.1	1
129	Variability of mycophenolate mofetil trough levels in stable kidney transplant patients. <i>Transplantation Proceedings</i> , 2007 , 39, 2185-6	1.1	5
128	Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 13-58	6.2	406
127	Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 175-85	6.2	20
126	Pharmacokinetics of mycophenolic acid and estimation of exposure using multiple linear regression equations in Chinese renal allograft recipients. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 389-401	6.2	17
125	Therapeutic drug measurement of mycophenolic acid derivatives in transplant patients. 2007 , 40, 752-64		33
124	Simple reversed-phase liquid chromatographic assay for simultaneous quantification of free mycophenolic acid and its glucuronide metabolite in human plasma. 2007 , 846, 313-8		13
123	Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. 2007 , 21, 18-23		29

122	Time-dependent clearance of mycophenolic acid in renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2007 , 63, 741-52	3.8	56
121	Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. 2007 , 7, 2496-503		324
120	Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2007 , 63, 279-88	2.8	63
119	Verbesserung der Arzneimittelsicherheit durch Therapiemonitoring. 2007 , 155, 724-732		4
118	Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation. 2008 , 88, 104-110		22
117	Comparison of high-performance liquid chromatography and enzyme-multiplied immunoassay technique to monitor mycophenolic acid in paediatric renal recipients. 2008 , 23, 1859-65		20
116	Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia. 2008 , 14, 1165-73		22
115	Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantation. 2008 , 41, 667-74		22
114	A limited sampling strategy for tacrolimus in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2008 , 66, 467-72	3.8	32
113	Estimation of the area under the curve for mycophenolic acid in adult renal transplant patients with concomitant tacrolimus using a limited sampling strategy. 2008 , 33, 159-63		16
112	No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. 2008 , 33, 193-201		28
111	Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum. 2008 , 68, 1385-414		16
110	Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 827-38	6.2	66
109	Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection. 2008 , 68, 2505-33		16
108	Handbook of Drug Monitoring Methods. 2008 ,		8
107	Performance of limited sampling strategies for predicting mycophenolic acid area under the curve in thoracic transplant recipients. 2008 , 27, 325-8		8
106	Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT). 2008 , 48, 485-94		17
105	Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. 2008 , 23, 3514-20		64

104	Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYL glucuronide metabolites in stable thoracic transplant recipients. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 282-91	3.2	24
103	Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates. <i>Transplantation</i> , 2008 , 86, 269-74	1.8	48
102	Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 559-64	3.2	66
101	Mycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability. 2009 , 5, 341-51		8
100	Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis. 2009 , 43, 1020-7		14
99	Monitoring of mycophenolate mofetil in orthotopic heart transplant recipients--a systematic review. 2009 , 23, 171-7		6
98	Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. 2009 , 29, 7-16		21
97	Comparison of pharmacokinetics of mycophenolic acid and its metabolites between living donor liver transplant recipients and deceased donor liver transplant recipients. 2009 , 15, 1473-80		6
96	Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. 2009 , 36, 541-64		61
95	No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation. <i>European Journal of Clinical Pharmacology</i> , 2009 , 65, 1047-53	2.8	26
94	Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. 2009 , 34, 683-92		11
93	EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. 2009 , 23, 617-24		25
92	A limited sampling strategy for estimating mycophenolic acid area under the curve in adult heart transplant patients treated with concomitant cyclosporine. 2009 , 34, 89-101		12
91	Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. 2009 , 39, 407-14		14
90	Inadequate mycophenolic acid exposure and acute rejection in kidney transplantation. <i>Transplantation Proceedings</i> , 2009 , 41, 2104-5	1.1	9
89	Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. <i>Transplantation Proceedings</i> , 2009 , 41, 2102-3	1.1	3
88	The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. <i>Transplantation Proceedings</i> , 2009 , 41, 2313-6	1.1	32
87	Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease. <i>Transplantation Proceedings</i> , 2009 , 41, 3873-6	1.1	16

86	Validation of limited sampling strategy for estimation of mycophenolic acid exposure during the first year after heart transplantation. <i>Transplantation Proceedings</i> , 2009 , 41, 4277-84	1.1	8
85	Limited sampling strategies for mycophenolic acid in solid organ transplantation: a systematic review. 2009 , 5, 1079-97		18
84	Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 382-90	3.2	27
83	Early phase limited sampling strategy characterizing tacrolimus and mycophenolic acid pharmacokinetics adapted to the maintenance phase of renal transplant patients. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 467-74	3.2	25
82	Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. 2009 , 19, 626-34		63
81	Therapeutic monitoring of mycophenolate in transplantation: is it justified?. 2009 , 10, 179-87		30
80	Pharmacokinetic interaction between sodium valproate and mycophenolate in renal allograft recipients. <i>Transplantation</i> , 2009 , 88, 1143-5	1.8	11
79	Mycophenolic acid predose concentrations and renal function in a mouse model for progressive renal fibrosis. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 73-8	3.2	8
78	Cost-effectiveness analysis of individualized mycophenolate mofetil dosing in kidney transplant patients in the APOMYGRE trial. <i>Transplantation</i> , 2010 , 89, 1255-62	1.8	12
77	A reliable limited sampling strategy for the estimation of mycophenolic acid area under the concentration time curve in adult renal transplant patients in the stable posttransplant period. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 136-40	3.2	19
76	Mycophenolic acid exposure in high- and low-weight renal transplant patients after dosing with mycophenolate mofetil in the Opticept trial. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 224-7	3.2	16
75	Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. 2010 , 62, 2047-54		61
74	Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation. 2010 , 107, 631-6		28
73	Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. <i>British Journal of Clinical Pharmacology</i> , 2010 , 70, 567-79	3.8	17
72	Evaluation of inosin-5Pmonophosphate dehydrogenase activity during maintenance therapy with tacrolimus. 2010 , 35, 79-85		10
71	Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients. 2010 , 24, E116-23		9
70	Mycophenolic acid estimation by pooled sampling: a novel strategy. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 141-4	3.2	1
69	. 2010 ,		40

68	Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. 2010 , 5, 341-58		226
67	Mycophenolic acid area under the curve recovery time following rifampicin withdrawal. 2010 , 20, 51-3		4
66	State of the art in therapeutic drug monitoring. 2010 , 48, 437-46		11
65	Correlation between pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients. 2010 , 50, 1388-96		2
64	Oral Targeted Drug Delivery Systems: Enteric Coating. 2010 , 205-223		4
63	An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. 2010 , 16, 333-43		48
62	Therapeutic drug monitoring of mycophenolic acid: a potential treatment for lupus nephritis. 2010 , 78, 335-6		3
61	Strategies to prevent cellular rejection in pediatric heart transplant recipients. 2010 , 12, 391-403		6
60	Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. 2011 , 51, 309-20		50
59	Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil. <i>Transplantation</i> , 2011 , 92, 1244-51	1.8	21
58	Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: a consensus report. 2011 , 25, 65-77		20
57	Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. 2011 , 25, 58-64		52
56	Performance of the Roche Total Mycophenolic Acid assay on the Cobas Integra 4000, Cobas 6000 and comparison to LC-MS/MS in liver transplant patients. 2011 , 49, 1159-65		11
55	Immunosuppressive Drug Monitoring: Limitations of Immunoassays and the Application of Liquid Chromatography Mass Spectrometry. 2012 , 323-348		2
54	Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 29-39	6.2	21
53	Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis. 2012 , 96, 10-25		25
52	Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients. 2012 , 25, 680-6		16
51	Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 843-9	2.8	28

50	Evaluation of mycophenolic acid exposure using a limited sampling strategy in renal transplant recipients. 2013 , 37, 534-40		11
49	Inhibitory effect of ciprofloxacin on β -glucuronidase-mediated deconjugation of mycophenolic acid glucuronide. <i>Biopharmaceutics and Drug Disposition</i> , 2014 , 35, 275-83	1.7	17
48	Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?. 2014 , 27, 994-1004		22
47	Effects of mycophenolate mofetil on kidney function and phosphorylation status of renal proteins in Alport COL4A3-deficient mice. 2014 , 12, 56		5
46	Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 141-7	3.2	16
45	Similar MPA exposure on modified release and regular tacrolimus. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 353-7	3.2	7
44	Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 46-53	3.2	7
43	Short-term therapeutic drug monitoring of mycophenolic acid reduces infection: a prospective, single-center cohort study in Chinese living-related kidney transplantation. 2014 , 16, 760-6		5
42	Therapeutic Drug Monitoring of Mycophenolic Acid in Lupus Nephritis: A Review of Current Literature. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 711-7	3.2	13
41	What is the inpatient variability of mycophenolic acid trough levels?. 2015 , 19, 669-74		14
40	No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1086-96	3.8	10
39	To TDM or not to TDM in lupus nephritis patients treated with MMF?. 2015 , 30, 560-4		22
38	A comprehensive review of the published assays for the quantitation of the immunosuppressant drug mycophenolic acid and its glucuronidated metabolites in biological fluids. 2016 , 30, 721-48		12
37	Circadian variation of cytotoxicity and genotoxicity induced by an immunosuppressive agent "Mycophenolate Mofetil" in rats. 2016 , 33, 1208-1221		4
36	Application of liquid chromatography combined with mass spectrometry or tandem mass spectrometry for therapeutic drug monitoring of immunosuppressants. 2016 , 57-81		3
35	Free mycophenolic acid determination in human plasma ultrafiltrate by a validated liquid chromatography-tandem mass spectrometry method. 2017 , 31, e3976		7
34	Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients. 2017 , 38, 1566-1579		19
33	Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 29-36	3.2	12

32	Impact of gut microbiota on drug metabolism: an update for safe and effective use of drugs. 2017 , 40, 1345-1355		38
31	Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation. 2017 , 47, 916-922		8
30	Determination of Mycophenolic Acid and Mycophenolic Acid Glucuronide Using Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS). 2018 , 75, 18.21.1-18.21.8		2
29	Ex vivo binding of the immunosuppressant mycophenolic acid to dog and cat plasma proteins and the effect of co-incubated dexamethasone and prednisolone. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2018 , 41, 513-521	1.4	2
28	Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 877-893	6.2	16
27	Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low-dose tacrolimus, for renal allograft rejection in non-human primates. <i>International Immunopharmacology</i> , 2018 , 64, 201-207	5.8	2
26	Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 572-580	3.2	3
25	Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2433-2442	3.8	7
24	The development of a population physiologically based pharmacokinetic model for mycophenolic mofetil and mycophenolic acid in humans using data from plasma, saliva, and kidney tissue. <i>Biopharmaceutics and Drug Disposition</i> , 2019 , 40, 325-340	1.7	5
23	Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients. <i>International Journal of Clinical Pharmacy</i> , 2019 , 41, 1047-1055	2.3	2
22	Therapeutic Drug Monitoring of Micophenolate Mofetil in Cardiac Transplant Patients by Limited Sampling Strategy: An Update. 2019 ,		1
21	Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention. <i>Transplantation</i> , 2019 , 103, 2012-2030	1.8	19
20	Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 371-379	2.8	8
19	Comparison of plasma and oral fluid concentrations of mycophenolic acid and its glucuronide metabolite by LC-MS in kidney transplant patients. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 553-559	2.8	5
18	Tacrolimus and Mycophenolic Acid Blood Concentration and Cellular Rejection After Heart Transplantation in First Endomyocardial Biopsy. <i>Transplantation Proceedings</i> , 2020 , 52, 2094-2097	1.1	
17	Immunosuppressants. 2020 , 271-307		1
16	Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients. <i>Frontiers in Pharmacology</i> , 2020 , 11, 340	5.6	5
15	Area-under-the-Curve-Based Mycophenolate Mofetil Dosage May Contribute to Decrease the Incidence of Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2

14	Immunosuppressive Drugs. 2008 , 165-199		3
13	Multicenter evaluation of a new inosine monophosphate dehydrogenase inhibition assay for quantification of total mycophenolic acid in plasma. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 428-33	3.2	26
12	Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 445-55	3.2	14
11	A possible simplification for the estimation of area under the curve (AUC ₀₋₁₂) of enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 165-70	3.2	15
10	Generics in transplantation medicine: Randomized comparison of innovator and substitution products containing mycophenolate mofetil?. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2019 , 57, 506-519	2	5
9	Mycophenolic Acid pharmacokinetics early after kidney transplant. <i>Experimental and Clinical Transplantation</i> , 2013 , 11, 112-7	0.8	0
8	A comparison of the effect of cyclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2006 , 061120055829076	3.8	
7	Herz- und Herz-Lungen-Transplantation. 2010 , 831-846		
6	Clinical Use of Immunosuppressants. 2011 , 1308-1316		
5	Therapeutic drug monitoring of immunosuppressants. 2020 , 317-332		
4	Immunosuppression in Lung Transplantation. <i>Handbook of Experimental Pharmacology</i> , 2021 , 1	3.2	0
3	DataSheet_1.docx. 2020 ,		
2	Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation. 2022 , 42, 599-633		1
1	The combination of exposure to Tacrolimus, mycophenolic acid, Inosine 5?-Monophosphate Dehydrogenase activity and inhibition in the first week define early histological outcomes in renal transplant recipients.		0